Roche's Dreismann Lands on Nanogen's Board; Digene Names New R&D VP; Open Biosystems Hires S&M VP; and Others | GenomeWeb
NEW YORK (GenomeWeb News) — Heiner Dreismann has been named to the board of directors at Nanogen, the company said this week.
 
Dreismann is the current CEO of FasTraQ and previously served as president and CEO of Roche Molecular Systems
 
Dreismann became a director of Iconix Biosciences last week and last month became a director of GeneNews, formerly ChondroGene.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.